The OLB Group, Inc. - Common Stock (OLB)

Actions signal confidence in OLB's value as the Company drives its Stablecoin payments strategy forward

September 10, 2026 VivoSim Labs, Inc. (NASDAQ: VIVS) is targeting one of pharmaceutical development's most expensive challenges: identifying drug toxicity before a candidate reaches human clinical trials. Using its NAMkind™ 3D human liver and intestinal models combined with AI-powered predictive toxicology, VivoSim is developing tools designed to help pharmaceutical companies determine which drug candidates should advance, be modified or be discontinued earlier .

Net Loss Narrows 50.3% and Operating Expenses Decline 23.4% Year Over Year

NEW YORK, NY / ACCESS Newswire / August 14, 2026 / The OLB Group, Inc. (Nasdaq:OLB) ("OLB" or the "Company"), a leading provider of integrated payment, commerce and fintech solutions doing business as SecurePay, today announced that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") granting the Company an additional 180-calendar-day period, through January 25, 2027, to regain compliance with the $1.00 minimum bid price per share requirement set forth in the Nasdaq Listing Rules

NEW YORK, NY / ACCESS Newswire / April 1, 2026 / The OLB Group, Inc. (NASDAQ:OLB) ("OLB" or the "Company"), a diversified FinTech company providing integrated merchant services and payment processing solutions, today reported financial results for the fiscal year ended December 31, 2025, and outlined its strategic roadmap centered on AI-driven OmniCommerce, disciplined cost management, and a clear path toward profitability

NEW YORK, NY / ACCESS Newswire / February 18, 2026 / The OLB Group, Inc. (NASDAQ:OLB) ("OLB" or the "Company"), a diversified fintech company providing payment processing and digital asset technology solutions, today announced that it has entered into a securities purchase agreement with an institutional investor for the purchase and sale of 2,857,142 shares of its common stock (or prefunded warrants in lieu thereof) together with warrants to purchase up to 3,571,428 shares of common stock at combined purchase price of $1.05 per share and accompanying warrants. The warrants have an exercise price of $0.92 per share, are exercisable directly after effectiveness of the resale registration statement for the common stock underlying the warrants, and will have a term of five years from the effectiveness of the resale registration statement.